Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, and Pharmacokinetics of Single Rising s.c. (Stage 1) and i.v. (Stage 2) Doses of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers (Double-blind, Randomized, Placebo-controlled Within Dose Groups)

NCT02596217 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02596217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02596217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, and Pharmacokinetics of Single Rising s.c. (Stage 1) and i.v. (Stage 2) Doses of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers (Double-blind, Randomized, Placebo-controlled Within Dose Groups)
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2015
Completion date
June 30, 2017
Enrollment
80 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy